Maintenance

Thursday evening the 17th at 7 pm there will be a 5 minute disruption in TCIA as the primary firewalls are updated to the latest in-version software. On Thursday the 24th, there be another 5-10 minute disruption as the primary firewalls are moved to new hardware.

Child pages
  • ACRIN 6698/I-SPY2 Breast DWI (ACRIN 6698)
Skip to end of metadata
Go to start of metadata

Summary

The American College of Radiology Imaging Network (ACRIN) trial 6698 was a multi-center study to evaluate the effectiveness of quantitative diffusion weighted imaging (DWI) for assessing breast cancer response to neoadjuvant chemotherapy (NAC).   ACRIN 6698 was performed as a sub-study of the ongoing I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), an adaptive, multi-agent phase II trial designed to quickly identify new agents for breast cancer.  

Patients recruited for the I-SPY 2 TRIAL and enrolling at sites meeting DWI qualification requirements were eligible for the 6698 trial. 406 women with invasive breast cancer were prospectively enrolled to ACRIN 6698 at ten institutions between August 2012 to January 2015, and 272 were randomized to I‑SPY 2 experimental treatment or control arms. Patients underwent breast DWI using a 4-b value protocol, as well as standard T2-weighted and dynamic contrast enhanced (DCE) scans. MRI studies were conducted at 4 timepoints over the course of NAC: pre-treatment (T0), early-treatment after 3 cycles paclitaxel (T1), mid-treatment between paclitaxel and AC (T2) and post-treatment (T3). Of the 272 treated patients, 242 comprised the primary analysis cohort (30 were excluded for missing or non-evaluable DWI exams). This TCIA collection includes all MRI studies received by the UCSF image analysis lab, excluding studies with no analyzable acquisitions. A separate download option is provided to access only those studies in the primary analysis cohort. In addition, DWI test/retest data acquired at baseline or early-treatment in a subset of patients is included in the full collection and is available as a separate download option (N=89 subjects consented and imaged, 71 analyzable test/retest acquisition pairs).

ACRIN 6698 Trial Schema

The ACRIN 6698 image data set is currently a unique collection for investigating the utility of DWI for monitoring of response to neoadjuvant breast cancer treatment. While many smaller and/or single-site DWI studies have been published, the multi-center and quality-control aspects of this data allow investigators true evaluation of analysis techniques in the clinical trial environment. The multi-b value protocol also allows evaluation of higher order diffusion models and evaluation at two different clinically relevant b values (600 and 800 s/mm2). Furthermore, the embedded test-retest arm of the study will allow evaluation of repeatability and reproducibility of new DWI metrics and analysis techniques.

In addition to the original DWI data the collection includes derived ADC maps with manually delimited tumor segmentations from the primary study analysis (for all studies rated as analyzable in the QC evaluation), plus T2-weighted images, DCE images with derived enhancement maps, clinical data and outcome data (pathologic complete response [pCR] at surgery).

BMMR2 Challenge and data release schedule

A subset of the ACRIN 6698 collection will be used for the NCI QIN sponsored BMMR2 challenge (Breast Multiparametric MRI for prediction of NAC Response) starting in June 2021. The goal of the challenge is to identify image-based markers derived from DW-MRI, alone or in combination with DCE-MRI, with improved performance over whole-tumor mean ADC for predicting pCR following NAC for invasive breast cancer. To achieve this goal, a subset of the ACRIN 6698 MRI studies from 191 subjects with analyzable data at all of the 1st three timepoints (T0, T1 and T2) will be made available to research teams participating in the challenge. This cohort will be split 60%/40% into training and test groups with pCR outcome data provided for the training set only. To register for the challenge please visit the challenge hosting site MedICI Challenges and select the BMMR2 Challenge. 

Public release of this data collection will be done in a staged manner. For an initial sequestration period, estimated to be June - October 2021, ACRIN 6698 data will only be available to members of the ACRIN 6698 investigators network and researchers registered for the BMMR2 challenge, and only the 191 patient challenge subset will be provided. After the closing of the challenge the full collection with all pCR outcome data will be available to the ACRIN 6698 investigators network only for a further sequestration period of four months. Full public release of the collection is currently planned for March 1, 2022.

Acknowledgements

We would like to acknowledge the individuals and institutions that have made this collection possible.

  • The patients who have volunteered to participate in the ACRIN 6698 and I-SPY 2 Trials
  • The extensive network of I-SPY 2 investigators, patient advocates and study coordinators.
  • I-SPY 2 site radiology teams that have contributed substantially to the value of this archive. 
  • Support from the NIH including grants to UCSF (U01 CA225427, R01 CA132870) and ACRIN (U01 CA079778, U01 CA080098). 
  • The I-SPY 2 TRIAL is supported by the Quantum Leap Healthcare Collaborative.

Data Access

This is a limited access data set. Through October 29, 2021 only a limited study subset from 191 patients will be available to ACRIN 6698 investigators and registered participants in the BMMR2 challenge. From November 1, 2021 through February 28, 2022 the full collection will be available to ACRIN 6698 investigators. Full public access will be allowed starting on March 1, 2022. If you wish to participate in the BMMR2 challenge please register at https://qin-challenge-acrin.centralus.cloudapp.azure.com/. If you are a member of the ACRIN 6698 investigators or study planning team please contact wen.li@ucsf.edu. Redistribution of any portion of the data is not allowed prior to the public release. 

Click the Download button to save a ".tcia" manifest file to your computer, which you must open with the NBIA Data Retriever

Data TypeDownload all or Query/Filter
BMMR2 Training set (DICOM, 247 GB)

     

BMMR2 Testing set (DICOM, 162 GB)
ACRIN 6698 Test-retest set (DICOM, 63 GB)

Click the Versions tab for more info about data releases.

Please contact help@cancerimagingarchive.net  with any questions regarding usage.

Detailed Description

Image Statistics


Modalities

MR

Number of Participants


Number of Studies


Number of Series


Number of Images


Image Size (GB)

MRI Studies

Trial time points for MRI studies

The primary aim of ACRIN 6698 was the evaluation of breast diffusion weighted imaging (DWI) for the prediction of response to neoadjuvant chemotherapy (NAC) for invasive breast cancer. For this purpose, serial MRI studies were acquired over the course of treatment. The study schema for the ACRIN 6698 Trial is shown in Figure 1

MRI studies were performed at up to four time points in the course of NAC:

  1. Pre-treatment (T0, optional test/retest visit)
    Prior to randomization patients received an MRI study including T2weighted, 4 b‑value DWI, and dynamic contrast-enhanced (DCE) acquisitions.

For patients randomized onto a treatment arm of I‑SPY 2 subsequent MRI studies with the same required acquisitions were performed:

  1. Early-treatment (T1, optional test/retest visit)
    After 3 weeks of regimen 1 treatment (Paclitaxel with or without an experimental agent).
  2. Mid-treatment (T2)
    Between Paclitaxel and Anthracycline (AC) treatment regimens
  3. Post-treatment (T3)
    Following 4 cycles AC and prior to surgery.

“Coffee-break” style test/retest studies were done on a subset of patients under a separate informed consent. These were by preference done at the baseline visit but were also allowed at visit T1. A given patient could only have the test/retest scans at a single visit, and the total number of test/retest cases at any given site was limited (maximum 14) to ensure a wide representation of different scanners, sites and field strengths in the test/retest cohort.

ACRIN 6698 Schema showing 4 longitudinal MRIs

Figure 1. ACRIN 6698 study schema.

Imaging protocol and included original image series

MR imaging was performed on a 1.5 or 3.0 Tesla scanner using a dedicated breast radiofrequency coil. All studies for a given patient were required to be performed on the same scanner configuration (model, field strength and breast coil model). Subjects were imaged in the prone position. The image acquisition protocol included a localization scan and a minimum of three required acquisitions:

  1. T2weighted sequence
  2. DWI (b=0, 100, 600, 800 s/mm2, 3-direction)
  3. T1weighted DCE (80sec < phase duration < 100sec with at least 8 minutes continuous post-injection acquisition)

Protocol limits on scan parameters for these required acquisitions are given in an accompanying document ACRIN 6698 MRI Acquisition Parameters.

All required imaging was performed axially with full bilaterally coverage. For the TCIA collection all original images from these three acquisitions are included. Derived images submitted with the study including reformats, CAD software outputs and MIP images are not part of the collection. For the T2weighted acquisitions multiple series are included if they were generated as part of the standard reconstruction process on the scanner. For example, acquisitions utilizing Dixon techniques to create separate fat and water images will have multiple series in the collection. All images in the original DWI series are included, including directional diffusion images for cases where they were retained and submitted with the study. For some General Electric Medical Systems (GEMS) scanners employed in the trial the acquisition software allowed only 2 b-values in a single DWI acquisition. For studies on these scanners the four b-value protocol DWI consisted of three consecutive two b-value series ([0,800], [0,600] and [0,100] s/mm2). A separate “merged series multi-b” (MSMB) series containing all b>0 images from the three series plus a single b=0 s/mm2 image created by averaging the three acquired b=0 images was created for analysis and is also included in the collection. The MSMB series are identified by Series Number (0020,0011) ending in 28  by the string "MSMB" as part of the Series Description (0008,103e). The DICOM metadata fields in the MSMB series have been set to permit reading as a standard GEMS multi-b acquisition. During automated QC procedures, the MSMB acquisitions were rejected if any sequence related parameters other than the b value differed between the multiple two b-value acquisitions. The original 2-b acquisition series are also included in the collection.

For test/retest MRI studies the patient was initially positioned in the scanner and had scout, T2weighted and DWI acquisitions performed. The patient was then removed from the scanner bed and repositioned. The scout, T2weighted and DWI were repeated and then the DCE scans were conducted. All of these acquisitions were stored in a single MRI study for this collection.

Derived object series:

Derived objects from the DWI and DCE acquisitions are included for the convenience of the user. Some of these are not strictly DICOM compliant and may not be readable by all DICOM software packages. Parametric maps and segmentations are believed to be identical to those utilized in the primary analysis and test/retest repeatability analyses of the 6698 Trial, but in some cases modifications may have occurred in subsequent processing.

DWI “Package” for each study with analyzable diffusion scan

  1. 4 b-value DW Trace Images
    1. Multiple 2-b MSMB DWI acquisitions were combined (1 site)
    2. 3 directional DW images were geometrically averaged to generate trace images for studies where directional DWI data was saved
    3. DICOM enhanced MRI b-value field ( 0018,9087 ) has been populated in all images with the appropriate b-value
    4. Image order was standardized
  2. 4-b value ADC maps
    1. A low threshold (b=0 image > 10) was applied to all studies to suppress background pixels
    2. ADC was calculated as linear fit to log(S(b)) = log(S(0)) – ADC * b
    3. Voxels below threshold or with ADC < 0.0 were set to 0
  3. Manually defined multi-slice tumor segmentations
    1. ROIs defined for published primary analysis
    2. Tumor segmented on all slices with identifiable tumor referencing high-b image, ADC map, and DCE subtraction image (for localization)
    3. The segmentations are provided both as DICOM SEG objects and as DICOM MRI objects on TCIA

These DWI derived series can be identified either by Series Description (0008,103e) or by Series Number (0020,0011). See Table 1 for series identification details.

Manual DWI Whole-Tumor Segmentation Method

The segmentations provided in the derived diffusion objects are those generated for and used in the primary analysis and test/retest analyses for the ACRIN 6698 study. Tumor was identified on post-contrast DCE subtraction images and then localized on the ADC map. Multi-slice, whole-tumor regions of interest (ROIs) were manually defined by selecting regions with low ADC and hyperintensity on a high b-value DWI (b=600 or 800 s/mm2) while avoiding adjacent adipose and fibroglandular tissue, biopsy clip artifacts, and regions of high T2 signal (e.g., seroma and necrosis). For multicentric/multifocal disease, all disease regions were included in the ROI. Region definition was done at the UCSF processing lab using in-house software tools developed with IDL (Exelis Visual Information Solutions, Boulder, Colorado).

DCE “Package” for each study

  1. Single-breast ipsilateral cropped DCE images
    1. As this was done primarily for computational efficiency, low matrix-sized images (<384 voxels per row) were stored and processed without cropping
    2. All maps and segmentations are based on these cropped images
  2. Enhancement maps
    1. PEearly: Percent enhancement at effective post-contrast time 120-150 sec
    2. PElate  : Percent enhancement at effective post-contrast time ~450 sec
    3. SER: Signal enhancement ratio    SER =  PEearly / PElate
      Note: SER values were scaled by 1000 to allow integer storage. DICOM software utilizing the rescale slope and intercept fields [ DICOM fields (0028, 1052-1054)] should return the original SER values in the range from 0.0 – 3.0.
    4. All maps are stored as DICOM MRI objects
  3. Functional Tumor Volume (FTV) analysis mask
    1. Image storing FTV masking processes on a pixel-by-pixel basis. The mask encodes:
      1. Pre-contrast background threshold
      2. Minimum PE threshold (70% nom.)
      3. Manually defined rectangular volume of interest (VOI) for enhancing tumor analysis
      4. Manually defined “OMIT” regions used to exclude non-tumor enhancing regions that encroached on the rectangular VOI
    2. Stored as DICOM SEG object in a separate series (see Table 1)
    3. Download Analysis mask files description for further information:

These DCE derived series can be identified either by Series Description (0008,103e) or by Series Number (0020,0011). See Table 1 for series identification details.

Table 1. Series identification for derived DWI and DCE objects

Data type

Series number

Series Description Match

DWI     root directory #

Siemens, GE (4b):   <root> = Original DWI series number

GE (MSMB):               <root> = <1st original series>28

Philips:                        <root> = Original DWI series number / 100

TRACE Images

<root>0100

ACRIN-6698: *DWI TRACE*

ADC Maps

<root>0200

ACRIN-6698: *ADC*

Whole tumor mask

<root>9000

ACRIN-6698: *DWI MASK*

Whole tumor segmentation

<root>9100

ACRIN-6698: *DWI SEG*

Merged 2b series (MSMB)<root>ACRIN-6698: MergedMSMB*

DCE     root directory #

Siemens, GE: <root> = 1st original DCE series number

Philips:            <root> = Original DCE series number / 100

SER Map

<root>1000

ISPY2: VOLSER: uni-lateral cropped: SER

PE phase <n> Map

<root>100<n>

ISPY2: VOLSER: uni-lateral cropped: PE<n>

Ipsilateral cropped Original

<root>1800

ISPY2: VOLSER: uni-lateral cropped: original DCE

FTV Analysis Mask

<root>1900

ISPY2: VOLSER: uni-lateral cropped: Analysis Mask

  1. For studies with test/retest DWI scans the prefixes on the series descriptions for the derived DWI objects will be “ACRIN 6698: TrT0:” and “ACRIN 6698: TrT1” for the 1st and 2nd scans respectively.
  2. FTV Analysis Masks are bit-encoded segmentations encoding all masking steps in the I‑SPY 2 primary FTV analysis. See document Analysis mask files description for a full description of these objects.
  3. DCE images with less than 384 voxels/row were not cropped for the FTV analysis. For these studies the derived DCE objects are all full bilateral images.

DICOM Dictionary for UCSF Private Attributes in Derived Objects:

Calculation parameters and DCE volume analysis results are included in private attributes in some of the derived objects. ACRIN 6698 ISPY2 Shared Private Tag Data Dictionary and ACRIN 6698 ISPY2 DWI and DCE MRI Data Descriptions files are provided for download for researchers wishing to use these parameters and/or results from the primary analyses. Note: the DCE functional tumor volume (FTV) results stored in the SER derived objects are NOT identical to those used in the I‑SPY 2 study due to differences in implementations on different platforms (UCSF in-house software vs. Hologic Inc. AEGIS system). While the differences are generally small and the AEGIS system was validated against the UCSF results in the prior I‑SPY 1 TRIAL, identical results cannot be guaranteed.

Image Quality Control System

ACRIN 6698 analysis included use of an image quality control system developed specifically for determination of the analyzability of breast DWI for quantitative cancer treatment monitoring. The image quality control system was comprised of three sequential but independent assessment stages: protocol compliance, image quality and usability, and ROI confidence. Since protocol compliance, image quality, and ROI confidence varied between exams for the same patient, each step was performed independently for each MRI exam.

Protocol Compliance Assessment

First, image metadata in DICOM tags was assessed for compliance with specified imaging parameters. Deviations from the specified imaging protocol were documented and classified into minor (non-critical to study aims) and major (critical to the study aims). Images exhibiting major protocol deviations were flagged and omitted from further analysis.

Image Quality and Usability Assessment

Next, the overall image quality and the usability of images for the study endpoints were evaluated. Readers scored image quality using a standard letter grading scale of A (best), B (good), C (average), D (poor) and F (worst) on fat suppression, severity of artifacts (displacement, ghosts, and distortions) and signal-to-noise ratio (SNR). These metrics were selected to reflect the most common and debilitating limitations in breast DWI. Fat suppression and SNR were scored using only the b=0 images while the severity of artifacts was evaluated using all DWI images. Scores were assigned numeric values (A=4 to F=0) and the geometric mean of the scores for fat suppression, artifacts and SNR was computed to yield a composite quality score. Each composite quality score was classified into overall high-, moderate-, or low-quality categories.

Separate from this image quality assessment, a subjective pass/fail assessment was made of image usability for evaluating diffusion parameters such as lesion ADC. This criterion was established to ensure that images of sufficient quality to address the scientific aim of the study were not rejected, e.g., a poor quality score due to excessive imaging artefacts might not result in rejection if the artefacts did not encroach on the region of the enhancing tumor.

ROI Confidence Assessment

After the full multi-slice/multi-region ROIs were placed, they were scored qualitatively based on reader confidence that the ROI faithfully represented the tissue of interest. The goal was to characterize the whole tumor while excluding fat, tissue, and tumor necrosis. ROIs were scored on a numerical scale of 3 for high confidence, 2 for moderate confidence and 1 for low confidence. Inclusion in the primary analysis was determined based on the image quality and ROI confidence assessments.

Patient cohorts in the shared collection

Figure 2 shows the enrollment numbers and exclusions used to determine the analysis cohort for the primary analysis. For this TCIA collection we include MRI studies from 385 of the 388 eligible subjects, three being excluded due to having no analyzable MRI studies received by the central imaging lab. The 116 patients excluded from the primary analysis as “Not Randomized” were those screened out of I‑SPY 2, most commonly due to being in the low-risk category (HR+/HER2- subtype with low MammaPrint score). Note that all these patients have baseline MRI studies included in this collection, and some were included in the ACRIN 6698 test/retest repeatability arm. A separate TCIA download option is provided for researchers who wish to focus on the 242-patient cohort used in the primary analysis. These subjects all had MRI studies with DWI scans that passed the QC evaluations at baseline and at at least one later time point. One other download option is provided for the 71-patient cohort with analyzable test/retest, primarily for use in the BMMR2 challenge and for researchers wishing to check reproducibility while focusing on the smaller 242 patient analysis cohort. The primary aim and test/retest studies are the only ones guaranteed to have tumor segmentations and DWI derived objects in this collection.

Figure 2. Derivation of the primary analysis cohort for ACRIN 6698. To be included in the primary analysis patients were required to have analyzable DW-MRI acquisitions at baseline (T0, pre-treatment) and for at least 1 subsequent study time point.

Processing and transfer history for MRI studies in this collection

The processing of the MR image data for this ACRIN 6698 collection consisted of the following steps between image acquisition and the creation of this shared data set on TCIA:

  1. MRI studies were conducted on approved scanners and were transferred to a system on-site for further processing. In some cases, this may have included an intermediate transfer to the site’s PACs system.
  2. MRI studies were sent from the study centers to the ACRIN Core Lab using the ACR TRIAD program
  3. Image data were de-identified and centrally archived at the ACRIN Core Lab
  4. Archived data was downloaded to the Breast Imaging Research Program (BIRP) at the University of California, San Francisco (UCSF) for DWI ADC analysis and DCE volumetric analysis
  5. De-identified image data, derived analysis maps and segmentations, and ancillary data files were transferred from UCSF to TCIA for data sharing

While every effort was made to preserve the integrity of both the original image data and image meta-data (DICOM attributes, public and private), multiple file transfers and strict adherence to HIPAA guidelines for patient confidentiality may have resulted in loss of some data. 

Ancillary files for the ACRIN 6698 collection

The following links will download files with non-image information for this collection.

Citations & Data Usage Policy 

This is a limited access data set. Through October 29, 2021 only a limited study subset from 191 patients will be available to ACRIN 6698 investigators and registered participants in the BMMR2 challenge. From November 1, 2021 through February 28, 2022 the full collection will be available to ACRIN 6698 investigators. Full public access will be allowed starting on March 1, 2022. If you wish to participate in the BMMR2 challenge please register at https://qin-challenge-acrin.centralus.cloudapp.azure.com/. If you are a member of the ACRIN 6698 investigators or study planning team please contact wen.li@ucsf.edu. Redistribution of any portion of the data is not allowed prior to the public release. 

Users of this data must abide by the TCIA Data Usage Policy and the Creative Commons Attribution-NonCommercial 4.0 International License under which it has been published. Attribution should include references to the following citations:

Data Citation

Newitt, D. C., Partridge, S. C., Zhang, Z., Gibbs, J., Chenevert, T., Rosen, M., Bolan, P., Marques, H., Romanoff, J., Cimino, L., Joe, B. N., Umphrey, H., Ojeda-Fournier, H., Dogan, B., Oh, K. Y., Abe, H., Drukteinis, J., Esserman, L. J., & Hylton, N. M. (2021). ACRIN 6698/I-SPY2 Breast DWI [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.KK02-6D95

Publication Citation

Newitt, D. C., Zhang, Z., Gibbs, J. E., Partridge, S. C., Chenevert, T. L., Rosen, M. A., Bolan, P. J., Marques, H. S., Aliu, S., Li, W., Cimino, L., Joe, B. N., Umphrey, H., Ojeda‐Fournier, H., Dogan, B., Oh, K., Abe, H., Drukteinis, J., … Esserman, L. J. (2018). Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. Journal of Magnetic Resonance Imaging, 49(6), 1617–1628. https://doi.org/10.1002/jmri.26539     

Partridge, S. C., Zhang, Z., Newitt, D. C., Gibbs, J. E., Chenevert, T. L., Rosen, M. A., Bolan, P. J., Marques, H. S., Romanoff, J., Cimino, L., Joe, B. N., Umphrey, H. R., Ojeda-Fournier, H., Dogan, B., Oh, K., Abe, H., Drukteinis, J. S., Esserman, L. J., & Hylton, N. M. (2018). Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology, 289(3), 618–627. https://doi.org/10.1148/radiol.2018180273 

TCIA Citation

Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. DOI: 10.1007/s10278-013-9622-7

Other Publications Using This

TCIA maintains a list of publications which leverage our data. If you have a publication you'd like to add please contact the TCIA Helpdesk.

Version 1: Current

Data TypeDownload all or Query/Filter
BMMR2 Training set (DICOM, 247 GB)

     

BMMR2 Testing set (DICOM, 162 GB)
ACRIN 6698 Test-retest set (DICOM, 63 GB)





















  • No labels